Search Results 1-10 of 15527 for Humira

  1. Adalimumab (subcutaneous route) - Mayo Clinic

    Brand Name. US Brand Name. ABRILADA. Amjevita. Cyltezo. Hadlima. Hulio. Humira. Hyrimoz. Idacio. Simlandi. Yuflyma. Yusimry. Back to top. Description.

  2. A Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients with Moderately to Severely Active Crohn's Disease - Mayo Clinic

    A Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients with Moderately to Severely Active Crohn's Disease · Overview.

  3. Adalimumab-aqvh (subcutaneous route) - Mayo Clinic

    Adalimumab-aqvh injection is used to treat the symptoms and prevent the progression of moderate to severe rheumatoid arthritis and ankylosing spondylitis. It is ...

  4. A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) - Mayo Clinic

    A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) · More about research at Mayo Clinic · Mayo ...

  5. Adalimumab-afzb (subcutaneous route) - Mayo Clinic

    Adalimumab-afzb injection is used to treat the symptoms and prevent the progression of moderate to severely active rheumatoid arthritis and active ankylosing ...

  6. Adalimumab-atto (subcutaneous route) - Mayo Clinic

    It is used in children 2 years of age and older for juvenile idiopathic arthritis. This medicine is also used to treat psoriatic arthritis, which is a type of ...

  7. Adalimumab-adaz (subcutaneous route) - Mayo Clinic

    Adalimumab-adaz injection is used to treat the symptoms and prevent the progression of moderate to severely active rheumatoid arthritis and active ankylosing ...

  8. Adalimumab-ryvk (subcutaneous route) - Mayo Clinic

    Adalimumab-ryvk injection is used to treat the symptoms and prevent the progression of moderate to severe rheumatoid arthritis. It is used in children 2 years ...

  9. Head-to-head comparison between vedolizumab and adalimumab for treatment of moderately to severely active ulcerative colitis - Mayo Clinic

    The Food and Drug Administration approved the use of anti-tumor necrosis factor and anti-integrin agents for the treatment of ulcerative colitis in 2005 ...

  10. Rheumatoid arthritis - Diagnosis and treatment - Mayo Clinic

    Also known as biologic response modifiers, this newer class of DMARDs includes abatacept (Orencia), adalimumab (Humira), anakinra (Kineret), certolizumab ...